Clinical quality impact: The decision increases the need for a clear, evidence-based Go/No-Go record.
Regulatory impact: Amgen must maintain protocol compliance, authority communication, and complete trial documentation.
Patient-safety impact: Clinical teams must continue follow-up and safety reporting after development ends.
Amgen Drops AMG-513 as MariTide Becomes Its Obesity Priority
Amgen confirmed the AMG-513 discontinuation in its second-quarter update but did not explain the reason. The FDA previously placed the Phase 1 study on clinical hold, and Amgen resumed enrollment after the agency lifted that hold in 2025. However, Amgen has not linked the earlier hold to its latest decision. Therefore, quality and regulatory teams should not assume causation without evidence.
Meanwhile, Amgen continues to expand MariTide through Phase 3 studies in weight management, cardiovascular outcomes, heart failure, obstructive sleep apnea, and switching from weekly incretin therapies. This contrast shows a focused portfolio choice: Amgen is concentrating late-stage investment in its lead obesity program while closing an earlier path.
Ending Development Does Not End Amgen’s Clinical Obligations
The decision changes a practical question for pharmaceutical leaders: when should a sponsor stop future development but continue trial obligations? Commercial value alone cannot answer it. Teams must assess participant safety, benefit–risk evidence, protocol commitments, data completeness, and regulatory correspondence.
The table below turns that decision into immediate responsibilities for the teams overseeing a discontinued program.
| Role | Main risk | Immediate action | Required evidence | Deadline |
|---|---|---|---|---|
|
Clinical Quality |
Weak decision governance |
Approve a discontinuation assessment |
Signed Go/No-Go record |
Within 15 business days |
|
Regulatory Affairs |
Inconsistent authority communication |
Reconcile commitments and notifications |
Regulatory correspondence log |
Before the next authority contact |
|
Safety and PV |
Incomplete participant follow-up |
Confirm ongoing surveillance and reporting |
Safety follow-up plan |
Immediately |
|
Clinical Operations |
Loss of control after development stops |
Confirm site, vendor, and closeout duties |
Updated responsibility matrix |
Before closeout |
Decision challenge: If an early Phase 1 asset no longer meets the portfolio threshold, should the sponsor stop immediately or complete participant follow-up? The defensible choice depends on patient protection, protocol duties, unresolved safety questions, and the value of the remaining data.
FDA Holds and Phase 1 Follow-Up Will Shape Amgen’s Next Move
The next signals will include Amgen’s explanation, the final Phase 1 status, and any update on its next-generation incretin and non-incretin programs. Quality leaders should also watch Amgen’s FDA discussions on reopening two subcutaneous BLINCYTO studies under partial clinical holds. These developments will show how the company governs stop, pause, and advance decisions across one portfolio.
An asset may leave the pipeline, but its safety follow-up, governance records, and regulatory commitments do not disappear with it. Zamann Pharma Support’s Quality Management System service offers a practical way to keep those obligations controlled, traceable, and ready for regulatory scrutiny.
Source: Endpoints.News.Com